Schatz Pharmaceauticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 22.63%
- Profit Growth 71.44%
- Ebitda -9.08%
- Net Worth -2.81%
- Total Assets -20.32%
About Schatz Pharmaceauticals
Schatz Pharmaceauticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 September 2015 (Nine years and four months 29 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Isharullah Siddiki and Kausar Jahan serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51397DL2015PTC285741
- Company No.
285741
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Schatz Pharmaceauticals Private Limited offer?
Schatz Pharmaceauticals Private Limited offers a wide range of products and services, including Herbal & Ayurvedic Medical Services, Ayurvedic Treatment.
Who are the key members and board of directors at Schatz Pharmaceauticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Isharullah Siddiki  | Director | 29-Sep-2015 | Current |
| Kausar Jahan | Director | 31-Mar-2017 | Current |
Financial Performance of Schatz Pharmaceauticals.
Schatz Pharmaceauticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.63% increase. The company also saw a substantial improvement in profitability, with a 71.44% increase in profit. The company's net worth dipped by a decrease of 2.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Schatz Pharmaceauticals?
In 2017, Schatz Pharmaceauticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Schatz Pharmaceauticals?
Unlock and access historical data on people associated with Schatz Pharmaceauticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Schatz Pharmaceauticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Schatz Pharmaceauticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
